- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/605 - Glucagons
Détention brevets de la classe C07K 14/605
Brevets de cette classe: 1582
Historique des publications depuis 10 ans
|
97
|
113
|
91
|
134
|
138
|
136
|
166
|
141
|
152
|
88
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novo Nordisk A/S | 2285 |
109 |
| Zealand Pharma A/S | 254 |
82 |
| Hanmi Pharm. Co., Ltd. | 571 |
81 |
| Eli Lilly and Company | 3840 |
73 |
| Sanofi | 4040 |
47 |
| Indiana University Research and Technology Corporation | 799 |
21 |
| Sun Pharmaceutical Industries Limited | 753 |
18 |
| Merck Sharp & Dohme LLC | 3749 |
18 |
| MedImmune Limited | 616 |
17 |
| The Trustees of the University of Pennsylvania | 4317 |
15 |
| Hanmi Science Co., Ltd. | 134 |
15 |
| I2o Therapeutics, Inc. | 31 |
15 |
| Takeda Pharmaceutical Company Limited | 2714 |
14 |
| Hybio Pharmaceutical Co., Ltd. | 121 |
14 |
| Intarcia Therapeutics, Inc. | 99 |
14 |
| The Scripps Research Institute | 1348 |
14 |
| Boehringer Ingelheim International GmbH | 4665 |
13 |
| President and Fellows of Harvard College | 5972 |
13 |
| Duke University | 3065 |
12 |
| Bachem Holding AG | 40 |
12 |
| Autres propriétaires | 965 |